Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View item
  • Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Exploiting gene dependency to inform drug development for multiple myeloma.

Thumbnail
View/Open
Exploiting gene dependency to inform drug development for multiple myeloma.pdf (1.222Mb)
Date
2022-07-26
ICR Author
Went, Molly
Houlston, Richard
Author
Went, M
Hoang, PH
Law, PJ
Kaiser, MF
Houlston, RS
Type
Journal Article
Metadata
Show full item record
Abstract
Despite recent advances in therapy, multiple myeloma essentially remains an incurable malignancy. Targeting tumour-specific essential genes, which constitute a druggable dependency, potentially offers a strategy for developing new therapeutic agents to treat MM and overcome drug resistance. To explore this possibility, we analysed DepMap project data identifying 23 MM essential genes and examined the relationship between their expression and patient outcome in three independent series totalling 1503 cases. The expression of TCF3 and FLVCR1 were both significantly associated with progression-free survival. IKBKB is already a drug target in other diseases, offering the prospect of repurposing to treat MM, while PIM2 is currently being investigated as a treatment for the disease. Our analysis supports the rationale of using large-scale genetic perturbation screens to guide the development of new therapeutic agents for MM.
URI
https://repository.icr.ac.uk/handle/internal/5253
DOI
https://doi.org/10.1038/s41598-022-16940-7
https://doi.org/10.1038/s41598-022-16940-7
 
Collections
  • Genetics and Epidemiology
Subject
Antineoplastic Agents
Drug Development
Humans
Multiple Myeloma
Research team
Cancer Genomics
Language
eng
Date accepted
2022-07-18
License start date
2022-07-26
Citation
Scientific Reports, 2022, 12 (1), pp. 12696 -
Publisher
Springer Science and Business Media LLC

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.